ArticleThe oncologist2022

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.

Mohammad Jahanzeb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.